Granted Patent
B2
US 12,274,736 · App. 17/548,929 · Granted Apr 15, 2025
Hematopoietic growth factor proteins and analogs thereof and angiotensin converting enzyme inhibitors for treatment of radiation exposure
Inventors:
George N. Cox (Louisville, CO); Christie M. Orschell (Indianapolis, IN); Meetha Manek Medhora (Brookfield, WI); Brian Fish (Waukesha, WI)
Assignees:
Bolder Biotechnology, Inc.; Indiana University Research and Technology Corporation; The Medical College of Wisconsin, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Methods and compositions comprising hematopoietic growth factor proteins and/or protein analogs thereof and/or combinations thereof and angiotensin converting enzyme inhibitors to treat the acute and long term adverse effects of radiation exposure in subjects who have been or will be exposed to radiation are disclosed.
Claims (29)
1. A method of improving 90 day to 12 month survival from hematopoietic acute radiation syndrome (H-ARS) in a subject who has been exposed to radiation and has delayed effects of acute radiation exposure (DEARE), comprising administering to the subject a combination therapy comprising an effective dose of an angiotensin-converting enzyme inhibitor (ACEI) and an effective dose of at least one hematopoietic growth factor (HGF) or protein analog thereof or combinations thereof;
wherein the ACEI is selected from the group consisting of lisinopril, perindopril, captopril, enalapril, and ramipril; and
wherein the HGF or protein analog thereof is selected from the group consisting of:
a granulocyte colony-stimulating factor (G-CSF) analog comprising a methionine at the N-terminus of SEQ ID NO:1;
a G-CSF analog comprising a cysteine residue substituted for A141 of G-CSF having SEQ ID NO:1 and a serine residue substituted for C17 of G-CSF having SEQ ID NO:1;
a granulocyte-macrophage colony-stimulating factor (GM-CSF) analog (SEQ ID NO:2);
a GM-CSF analog comprising a cysteine substitution at amino acid position 3 of SEQ ID NO: 2;
an interleukin-11 (IL-11) analog comprising a cysteine residue added following the C-terminus of the protein having SEQ ID NO:3 or SEQ ID NO:7, wherein the P1 amino acid is deleted; and
combinations thereof; and
wherein the survival obtained by treatment with the combination of at least one HGF or protein analog thereof and the ACEI is greater than the survival obtained by treatment with at least one HGF or protein analog thereof alone or treatment with the ACEI alone.
2. The method of claim 1 , wherein the subject has been exposed to a myelosuppressive dose amount of radiation.
3. The method of claim 1 , wherein the G-CSF analog, the GM-CSF analog, or the IL-11 analog is modified with a polyethylene glycol (PEG).
4. The method of claim 1 , wherein the improved survival correlates with accelerated hematopoietic recovery in the subject.
5. The method of claim 1 , wherein the improved survival correlates with decreased lung morbidity in the subject.
6. The method of claim 1 , wherein the improved survival correlates with decreased lung pneumonitis in the subject.
7. The method of claim 1 , wherein the improved survival correlates with decreased lung fibrosis in the subject.
8. The method of claim 1 , wherein the improved survival correlates with decreased kidney morbidity in the subject.
9. The method of claim 1 , wherein the improved survival correlates with decreased heart morbidity in the subject.
10. The method of claim 1 , wherein the effective dose of the ACEI is administered concurrently with, prior to, or after administration of the effective dose of the at least one HGF or protein analog thereof or combinations thereof.
11. The method of claim 1 , wherein the effective dose of the at least one HGF or protein analog thereof is a single dose of 0.1 μg to 5 mg per kg of the subject.
12. The method of claim 1 , wherein the subject is administered one or more single doses of the at least one HGF or protein analog thereof or combinations thereof.
13. The method of claim 1 , wherein the subject is administered one or more doses of the at least one HGF or protein analog thereof or combination thereof beginning within 24 hours following the subject's exposure to the radiation.
14. The method of claim 1 , wherein the effective dose of the ACEI is a dose of 1.3 to 50 mg/m2/day.
15. The method of claim 1 , wherein the subject is administered the ACEI daily beginning within 7 days following the subject's exposure to the radiation.
16. The method of claim 1 , wherein the subject is administered the ACEI daily beginning within 7 days following the subject's exposure to radiation and continuing for 7 to 150 days following the subject's exposure to radiation.
17. The method of claim 1 , wherein the effective dose of the at least one HGF or protein analog thereof or combination thereof is administered to the subject beginning within 24 hours following radiation exposure and the effective dose of the ACEI is administered to the subject beginning within 7 days following radiation exposure.
18. The method of claim 1 , wherein the effective dose of the at least one HGF or protein analog thereof or combination thereof is administered to the subject beginning within 24 hours following radiation exposure, and the effective dose of the ACEI is administered to the subject beginning within 7 days following radiation exposure and continuing for 7 to 150 days following the subject's exposure to radiation.
19. The method of claim 1 , wherein the ACEI is lisinopril.
20. The method of claim 1 , wherein the HGF protein analog is a combination of the HGF protein analogs, wherein the combination consists of a G-CSF analog, a GM-CSF analog and an IL-11 analog, and wherein each analog is modified with a polyethylene glycol (PEG).
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 22, 2021
From: COX, GEORGE N.
To: BOLDER BIOTECHNOLOGY, INC.
Reel/Frame 058462/0991 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 22, 2021
From: MEDHORA, MEETHA MANEK; FISH, BRIAN
To: THE MEDICAL COLLEGE OF WISCONSIN, INC.
Reel/Frame 058463/0018 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 22, 2021
From: ORSCHELL, CHRISTIE M.
To: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
Reel/Frame 058580/0946 →
Continuity (3)
Provisional Application
62220819
· Sep 18, 2015
References Cited (152)
US 4810643A
· Souza
· 1989
[cited by applicant]
US 5437863A
· Williams et al.
· 1995
[cited by applicant]
US 6066317A
· Yang et al.
· 2000
[cited by applicant]
US 6555660B2
· Nissen et al.
· 2003
[cited by applicant]
US 6608183B1
· Cox, III
· 2003
[cited by applicant]
US 6753165B1
· Cox et al.
· 2004
[cited by applicant]
US 7148333B2
· Cox, III
· 2006
[cited by applicant]
US 7214779B2
· Cox, III
· 2007
[cited by applicant]
US 7232885B2
· Cox, III
· 2007
[cited by applicant]
US 7253267B2
· Cox, III
· 2007
[cited by applicant]
US 7306931B2
· Rosendahl et al.
· 2007
[cited by applicant]
US 7309781B2
· Cox, III
· 2007
[cited by applicant]
US 7371370B2
· Sarkar et al.
· 2008
[cited by applicant]
US 7495087B2
· Cox, III
· 2009
[cited by applicant]
US 7754855B1
· Cox, III et al.
· 2010
[cited by applicant]
US 7994124B2
· Cox
· 2011
[cited by applicant]
US 8133480B2
· Cox, III
· 2012
[cited by applicant]
US 8748392B2
· Cox, III
· 2014
[cited by applicant]
US 8841249B2
· Johansen et al.
· 2014
[cited by applicant]
US 9320777B2
· Cox et al.
· 2016
[cited by applicant]
US 20030064480A1
· Lauffer et al.
· 2003
[cited by applicant]
US 20100183543A1
· Yonehiro et al.
· 2010
[cited by applicant]
WO WO0187925
· 2001
[cited by applicant]
WO WO2005027978
· 2005
[cited by applicant]
WO WO2010033884
· 2010
[cited by applicant]
Medhora et al. Radiat. Re. 182, 545-555(2014) (Year: 2014).
[cited by examiner]
Plett et al. Health Phys. Jan. 2014; 106(1):7-20 (Year: 2014).
[cited by examiner]
Aagaard et al., “RNAi therapeutics: Principles, prospects and challenges,” Advanced Drug Delivery Reviews, 2007, vol. 59, Iss. 2-3, pp. 75-86.
[cited by applicant]
Abdel-Meguide et al., “Three-dimensional structure of a genetically engineered variant of porcine growth hormone,” Proc. Natl. Acad. Sci. USA, 1987, vol. 84, pp. 6434-6437.
[cited by applicant]
Arakawa et al., “Cysteine 17 of recombinant human granulocyte colony-stimulating factor is partially solvent-exposed,” J. Protein Chem., 1993, vol. 12, pp. 525-531.
[cited by applicant]
Barshishat-Kupper et al., “Captopril modulates hypoxia-inducible factors and erythropoietin responses in a murine model of total body irradiation”, Experimental Hematology, 2011, vol. 39, Iss. 3, pp. 293-304.
[cited by applicant]
Basile et al., “HemaMax™, a Recombinant Human Interleukin-12, Is a Potent Mitigator of Acute Radiation Injury in Mice and Non-Human Primates,” PLOS ONE, 2012, vol. 7, Iss. 2, e30434.
[cited by applicant]
Bazan, “Haemopoietic receptors and helical cytokines,” Immunology Today, 1990, vol. 11, pp. 350-354.
[cited by applicant]
Bertho et al., “Comparison of autologous cell therapy and granulocyte-colony-stimulating factor (G-CS) injection vs. G-CSF injection alone for the treatment of acute radiation syndrome in a non-human primate model,” Int…
[cited by applicant]
Blumberg et al., “Interleukin 20: Discovery, Receptor Identification, and Role in Epidermal Function,” Cell, 2001, vol. 104, pp. 9-19.
[cited by applicant]
Boerma et al. “Local administration of interleukin-11 ameliorates intestinal radiation injury in rats,” Cancer Res., 2007, vol. 67, pp. 9501-9506.
[cited by applicant]
Booth et al., “Acute Gastrointestinal Syndrome in High-Dose Irradiated Mice,” Health Physics, 2012, vol. 103, Iss. 4, pp. 383-399.
[cited by applicant]
Booth et al., “Protection against mucosal injury by growth factors and cytokines,” J National Cancer Institute Monographs, 2001, vol. 29, pp. 16-20.
[cited by applicant]
Bork, “Powers and Pitfalls in Sequence Analysis: The 70% Hurdle,” Genome Research, 2000, vol. 10, Iss. 4, pp. 398-400.
[cited by applicant]
Bowen et al., “Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor mutein,” Exp. Hematol., 1999, vol. 27, pp. 425-432.
[cited by applicant]
Bowie et al., “Deciphering the message in protein sequences: tolerance to amino acid substitutions,” Science, 1990, vol. 247, Iss. 4948, pp. 1306-1310.
[cited by applicant]
Brown et al. “Tolerance of single, but not multiple, amino acid replacements in antibody VH CDR 2: a means of minimizing B cell wastage from somatic hypermutation?,” Journal of Immunology, 1996, vol. 156, Iss. 9, pp. 32…
[cited by applicant]
Burgess et al., “Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single…
[cited by applicant]
Cairo et al., “Modulation of neonatal rat myeloid kinetics resulting in peripheral neutrophilia by single pulse administration of Rh granulocyte-macrophage colony-stimulating factor and Rh granulocyte colony-stimulating…
[cited by applicant]
Cairo, “Dose reductions and delays: limitations of myelosuppressive chemotherapy,” Oncology, 2000, vol. 14, pp. 21-31.
[cited by applicant]
Cantrell et al., “Cloning, sequence, and expression of a human granulocyte/macrophage colony-stimulating factor,” Proc. Natl Acad. Sci. USA, 1985, vol. 85, pp. 6250-6254.
[cited by applicant]
Carlo-Stella et al., “Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers,” Blood, …
[cited by applicant]
Charrier et al., “Inhibition of angiotensin I-converting enzyme induces radioprotection by preserving murine hematopoietic short-term reconstituting cells,” Blood, 2004, vol. 104, Iss. 4 pp. 978-985.
[cited by applicant]
Chen et al., “Growth hormone mitigates against lethal irradiation and enhances hematologic and immune recovery in mice and non-human primates,” PLoS One (www.plosone.org), 2010, vol. 5(6), e11056, 12 pages.
[cited by applicant]
Chua et al., “Survival Efficacy of the PEGylated G-CSFs Maxy-G34 and Neulasta in a Mouse Model of Lethal H-ARS, and Residual Bone Marrow Damage in Treated Survivors,” Health Physics, 2014, vol. 106, Iss. 1, pp. 21-38.
[cited by applicant]
Cleland et al., “A Novel Long-Acting Human Growth Hormone Fusion Protein (VRS-317): Enhanced In Vivo Potency and Half-Life,” Journal of Pharmaceutical Sciences, 2012, vol. 101, Iss. 8, pp. 2744-2754.
[cited by applicant]
Cox et al., “A long-acting, monoPEGylated human growth hormone analog is a potent stimulator of weight gain and bone growth in hypophysectomized rats,” Endocrinology, 2007, vol. 148, pp. 1590-1597.
[cited by applicant]
Cox et al., “Enhanced circulating half-life and hematopoietic properties of a human granulocyte colony-stimulating factor (G-CSF)-immunoglobulin fusion protein,” Exp. Hematol., 2004, vol. 32, pp. 441-449.
[cited by applicant]
Dainiak et al., “The Hematologist and Radiation Casualties,” Am. Soc. Hematology, 2003, pp. 473-496.
[cited by applicant]
Davis et al. “Timing of captopril administration determines radiation protection or radiation sensitization in a murine model of total body irradiation,” Experimental Hematology, 2010, vol. 38, Iss. 4, pp. 270-281.
[cited by applicant]
Davis et al. “Response to Moulder et al., Re: Davis et al., Timing of captopril administration determines radiation protection or radiation sensitization in a murine model of total body irradiation,” Experimental Hemato…
[cited by applicant]
Day et al. “Enhanced hematopoietic protection from radiation by the combination of genistein and captopril,” International Immunopharmacology, 2013, 15: 348-356.
[cited by applicant]
De Vos et al., “Human Growth Hormone and Extracellular Domain of Its Receptor: Crystal Structure of the Complex,” Science, 1992, vol. 255, pp. 306-312.
[cited by applicant]
DiCarlo et al., “Radiation injury after a nuclear detonation: medical consequences and the need for scarce resource allocation,” Disaster Med Public Health Prep, 2011, vol. 5(Suppl. 1), pp. S32-44.
[cited by applicant]
Doan et al., “Epidermal growth factor regulates hematopoietic regeneration following radiation injury” Nature Medicine, 2013, 19: 295-304.
[cited by applicant]
Doerks et al., “Protein annotation: detective work for function prediction,” Trends in Genetics, 1998, vol. 14, Iss. 6, pp. 248-250.
[cited by applicant]
Doherty et al., “Site-Specific PEGylation of Engineered Cysteine Analogues of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor,” Bioconjugate Chemistry, 2005, vol. 16, pp. 1291-1298.
[cited by applicant]
Drouet et al., “Cytokines in combination to treat radiation-induced myelosuppression: evaluation of SCF + glycosylated EPO + PEGylated G-CSF as an emergency treatment in highly irradiated monkeys,” Hematologica, 2008, v…
[cited by applicant]
Du et al., “A bone marrow stromal-derived growth factor, Interleukin-11, stimulates recovery of small intestinal mucosal cells after cytoablative therapy,” Blood, 1994, vol. 83, pp. 33-37.
[cited by applicant]
Du et al., Interleukin-11: review of molecular, cell biology and clinical use. Blood, 1997, vol. 89, pp. 3897-3908.
[cited by applicant]
Ersoy et al., “Effect of Growth Hormone on small intestinal homeostasis relation to cellular mediators IGF-I and IGFBP-3,” World J Gastroenterol, 2009, vol. 15, pp. 5418-5424.
[cited by applicant]
Fares et al., “Design of a long-acting follitropin agonist by fusing the C-terminal sequence of the chorionic gonadotropin ß subunit to the follitropin ß subunit,” Proceedings of the National Academy of Sciences of the …
[cited by applicant]
Farese et al. “The Ability of Filgrastim to Mitigate Mortality Following LD50/60 Total-body Irradiation Is Administration Time-Dependent,” Health Physics, 2014, vol. 106, Iss. 1, pp. 39-47.
[cited by applicant]
Farese et al., “A Nonhuman Primate Model of the Hematopoietic Acute Radiation Syndrome Plus Medical Management,” Health Physics, 2012, vol. 103, Iss. 4, pp. 367-382.
[cited by applicant]
Farese et al., “Filgrastim Improves Survival in Lethally Irradiated Nonhuman Primate,” Radiation Research, 2013, 179, Iss. 1, pp. 89-100.
[cited by applicant]
Farese et al. “Combination Protocols of Cytokine Therapy With Interleukin-3 and Granulocyte-Macrophage Colony-Stimulating Factor in a Primate Model of Radiation-Induced Marrow Aplasia,” Blood, Nov. 1993, vol. 82, No. 10…
[cited by applicant]
Gao et al., “Enalapril Mitigates Radiation-Induced Pneumonitis and Pulmonary Fibrosis if Started 35 Days after Whole-Thorax Irradiation,” Radiation Research, 2013, vol. 180, Iss. 5. pp. 546-552.
[cited by applicant]
Ghosh et al. “Renin-Angiotensin System Suppression Mitigates Experimental Radiation Pneumonitis,” International Journal of Radiation Oncology*Biology*Physics, 2009, vol. 75, Iss. 5, pp. 1528-1536.
[cited by applicant]
Glaspy, “Hematopoietic management in oncology practice. Part 1. Myeloid growth factors,” Oncology, 2003, vol. 17, pp. 1593-1603.
[cited by applicant]
Goeddel et al., “Direct expression in Escherichia coli of a DNA sequence coding for human growth hormone,” Nature, 1979, vol. 281(5732), pp. 544-548.
[cited by applicant]
Goldman, “Preclinical biology of Interleukin-11: a multifunctional hematopoietic cytokine with potent thrombopoietic activity,” Stem Cells, 1995, vol. 13, pp. 462-471.
[cited by applicant]
Goodson et al., “Site-Directed Pegylation of Recombinant Interleukin-2 at its Glycosylation Site,” Biotechnology, 1990, vol. 8, pp. 343-346.
[cited by applicant]
Gordon et al. “A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy,” Blood, 1996, vol. 87, Iss. 9, pp. 3615-3624.
[cited by applicant]
Hao et al., “Effects of Recombinant Human Interleukin 11 on Thrombocytopenia and Neutropenia in Irradiated Rhesus Monkeys,” Radiation Res., 2004, vol. 162, pp. 157-163.
[cited by applicant]
Himburg et al., “Pleiotrophin mediates hematopoietic regeneration via activation of RAS,” The Journal of Clinical Investigation, 2014, vol. 124, Iss, 11, pp. 4753-4758.
[cited by applicant]
Howarth et al., “Effects of insulin-like growth factor-I administration on radiation enteritis in rats,” Scand J Gastroenterol, 2003, vol. 32, pp. 1118-1124.
[cited by applicant]
Howarth, “Insulin-like growth factor-I and the gastrointestinal system: therapeutic indications and safety implications,” J. Nutr., 2003, vol. 133, pp. 2109-2112.
[cited by applicant]
Ihle et al., “Signaling Through the Hematopoietic Cytokine Receptors,” Annu. Rev. Immunol., 1995, vol. 13, pp. 369-398.
[cited by applicant]
Kawashima et al., “Molecular cloning of cDNA encoding adipogenesis inhibitory factor and identity with Interleukin-11,” FEBS Letts., 1991, vol. 283, pp. 199-202.
[cited by applicant]
Kiessling et al., “Functional expression of the Interleukin-11 receptor alpha chain and evidence of antiapoptotic effects in human colonic epithelial cells,” J. Biol. Chem., 2004, vol. 279:, pp. 10304-10315.
[cited by applicant]
Kitamura et al., “Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin,” J.Cell. Physiol., 1989, vol. 140, 323-334.
[cited by applicant]
Kma et al., “Angiotensin Converting Enzyme Inhibitors Mitigate Collagen Synthesis Induced by a Single Dose of Radiation to the Whole Thorax,” Journal of Radiation Research, 2012, vol. 53, Iss. 1, pp. 10-17.
[cited by applicant]
Kubota et al., “Structural characterization of natural and recombinant human granulocyte colony-stimulating factors,” J. Biochem., 1990, vol. 107, pp. 486-492.
[cited by applicant]
Lazar et al., “Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities,” Molecular and Cellular Biology, 1988, vol. 8, Iss. 3, pp. 1247-1252.
[cited by applicant]
Lee et al., “Isolation of cDNA for a human granulocyte-macrophage colony-stimulating factor by functional expression in mammalian cells,” Proc. Natl. Acad. Sci. USA, 1985, vol. 82, pp. 4360-4364.
[cited by applicant]
Leonard et al., “Recombinant human interleukin-11 stimulates multilineage hematopoietic recovery in mice after a myelosuppressive regimen of sublethal irradiation and carboplatin,” Blood, 1994, vol. 83, pp. 1499-1506.
[cited by applicant]
Lu et al., “Disulfide and secondary structures of recombinant human granulocyte colony-stimulating factor,” Arch. Biochem. Biophys., 1989, vol. 268, pp. 81-92.
[cited by applicant]
Macvittie, “Defining the full therapeutic potential of recombinant growth factors in the post radiation-accident environment: the effect of supportive care plus administration of G-CSF,” Health Phys., 2005, vol. 89, pp.…
[cited by applicant]
Martial et al., “Human growth hormone: complementary DNA cloning and expression in bacteria,” Science, 1979, vol. 205(4406), pp. 602-607.
[cited by applicant]
Mayer et al., “Efficacy of recombinant human granulocyte-macrophage colony-stimulating factor in rhesus monkeys,” Ann N Y Acad Sci, 1987, vol. 511, pp. 17-29.
[cited by applicant]
Mayer et al., “In vitro and in vivo activity of human recombinant granulocyte-macrophage colony-stimulating factor in dogs,” Exp. Hematol., 1990, vol. 18, pp. 1026-1033.
[cited by applicant]
Mayer et al., “Recombinant human GM-CSF induces leukocytosis and activates peripheral blood polymorphonuclear neutrophils in nonhuman primates,” Blood, 1987, vol. 70, pp. 206-213.
[cited by applicant]
Mayer et al., “Recombinant murine granulocyte-macrophage colony-stimulating factor augments neutrophil recovery and enhances resistance to infections in myelosuppressed mice,” J. Infect. Dis., 1991, vol. 163, pp. 584-59…
[cited by applicant]
Medhora et al., “Mitigation of Radiation-Induced Injuries to Multiple Organs in Rats by FDA-Approved Drugs and Supportive Care,” International Journal of Radiation Oncology, Biology, Physics, 2014, vol. 90, Iss. 1 Suppl…
[cited by applicant]
Medhora et al., “Model Development and Use of ACE Inhibitors for Preclinical Mitigation of Radiation-Induced Injury to Multiple Organs,” Radiation Research, 2014, vol. 182, Iss. 5, pp. 545-555.
[cited by applicant]
Molteni et al., “Control of radiation-induced pneumopathy and lung fibrosis by angiotensin-converting enzyme inhibitors and an angiotensin II type 1 receptor blocker,” International Journal of Radiation Biology, 2000, v…
[cited by applicant]
Mott et al., “Four-helix bundle growth factors and their receptors: protein-protein interactions,” Current Opinion in Structural Biology, 1995, vol. 5, pp. 114-121.
[cited by applicant]
Moulder et al., “Captopril and Losartan for Mitigation of Renal Injury Caused by Single-Dose Total-Body Irradiation,” Radiation Research, 2011, vol. 175, Iss. 1, pp. 29-36.
[cited by applicant]
Moulder et al., “Mitigation of experimental radiation nephropathy by renin-equivalent doses of angiotensin converting enzyme inhibitors,” International Journal of Radiation Biology, 2014, vol. 90, Iss. 9, pp. 762-768.
[cited by applicant]
Moulder et al., “Re: Davis et al., “Timing of captopril administration determines radiation protection or radiation sensitization in a murine model of total body irradiation”,” Experimental Hematology, 2011, vol. 39, Is…
[cited by applicant]
Mylonas et al., “Growth Hormone and insulin-like growth factor I protect intestinal cells from radiation induced apoptosis,” Mol Cell Endocrinol., 2000, vol. 160, pp. 115-122.
[cited by applicant]
Nagata et al., “Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor,” Nature, 1986, vol. 319(6052), pp. 415-418.
[cited by applicant]
Nagata et al., “The chromosomal gene structure and two mRNAs for human granulocyte colony-stimulating factor,” EMBO J., 1986, vol. 5, pp. 575-581.
[cited by applicant]
Neta et al., “Cytokines in radiation injury,” Blood, 1988, vol. 72, pp. 1093-1095.
[cited by applicant]
Neta et al., “Interdependence of the radioprotective effects of human recombinant interleukin-1 alpha, tumor necrosis factor, granulocyte colony-stimulating factor, and murine recombinant granulocyte-macrophage colony-s…
[cited by applicant]
Paul et al., “Molecular cloning of a cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine,” Proc. Natl. Acad. Sci. USA, 1990, vol. 87, pp. 7512-7516.
[cited by applicant]
Picken et al., “Nucleotide sequence of the gene for heat-stable enterotoxin II of
[cited by applicant]
Plett et al., “Establishing a Murine Model of the Hematopoietic Syndrome of the Acute Radiation Syndrome,” Health Physics, 2012, vol. 103, Iss. 4, pp. 343-355.
[cited by applicant]
Plett et al., “PEGylated G-CSF (BBT-015), GM-CSF (BBT-007), and IL-11 (BBT-059) Analogs Enhance Survival and Hematopoietic Cell Recovery in a Mouse Model of the Hematopoietic Syndrome of the Acute Radiation Syndrome,” H…
[cited by applicant]
Potten, “Interleukin-11 protects the clonogenic stem cells in murine small-intestinal crypts from impairment of their reproductive capacity by radiation,” Int. J. Cancer, 1995, vol. 62, pp. 356-361.
[cited by applicant]
Potten, “Protection of the small intestinal clonogenic stem cells from radiation-induced damage by pretreatment with interleukin-11 also increases murine survival time,” Stem Cells, 1996, vol. 14, pp. 452-459.
[cited by applicant]
Raguso et al., “Protective effects of recombinant growth hormone on intestinal mucosa in rats receiving abdominal radiotherapy,” Clin Nutr., 2002, vol. 21, pp. 487-490.
[cited by applicant]
Redlich et al., “IL-11 enhances survival and decreases TNF production after radiation-induced thoracic injury,” J Immunology, 1996, vol. 157, pp. 1705-1710.
[cited by applicant]
Rosendahl et al., “Site-specific protein PEGylation: application to cysteine analogs of recombinant human granulocyte colony-stimulating factor,” BioProcess International, 2005, vol. 3, pp. 52-62.
[cited by applicant]
Schuening et al., “Effect of recombinant human granulocyte colony-stimulating factor on hematopoiesis of normal dogs and on hematopoietic recovery after otherwise lethal total body irradiation,” Blood, 1989, vol. 74, pp…
[cited by applicant]
Schwertschlag et al., “Hematopoietic, immunomodulatory and epithelial effects of interleukin-11,” Leukemia, 1999, vol. 13, pp. 1307-1315.
[cited by applicant]
Sirohi et al., “Use of physiological doses of human growth hormone in haematological patients receiving intensive chemotherapy promotes haematopoietic recovery: a double blind randomized, placebo-controlled study,” Bone…
[cited by applicant]
Sitaraman et al., “Oprelvekin. Genetics Institute,” Curr. Opin. Investig. Drugs, 2001, vol. 2, pp. 1395-1400.
[cited by applicant]
Skolnick et al., “From genes to protein structure and function: novel applications of computational approaches in the genomic era,” Trends in Biotechnology, 2000, vol. 18, Iss. 1, pp. 34-39.
[cited by applicant]
Sonis et al., “Defining mechanisms of action of interleuikin-11 on the progression of radiation-induced oral mucositis in hamsters,” Oral Oncology, 2000, vol. 36, pp. 373-381.
[cited by applicant]
Souza et al., “Recombinant Human Granulocyte Colony-Stimulating Factor: Effects on Normal and Leukemic Myeloid Cells,” Science, 1986, vol. 232, pp. 61-65.
[cited by applicant]
Stribling et al., “Aerosol gene delivery in vivo,” Proceedings of the National Academy of Sciences of the United States of America, 1992, vol. 89, Iss. 23, pp. 11277-11281.
[cited by applicant]
Swierczewska et al. “What is the future of PEGylated therapies?” Expert Opinion on Emerging Drugs, 2015, vol. 20, No. 4, pp. 531-536.
[cited by applicant]
Takagi et al., “Enhanced pharmacological activity of recombinant human interleukin-11 (rhIL-11) by chemical modification with polyethylene glycol,” J. Controlled Research, 2007, vol. 119, pp. 271-278.
[cited by applicant]
Tokuriki et al., “Stability effects of mutations and protein evolvability,” Current Opinion in Structural Biology, 2009, vol. 19, Iss. 5, pp. 596-604.
[cited by applicant]
Uckun et al., “In vivo radioprotective effects of recombinant human granulocyte colony- stimulating factor in lethally irradiated mice,” Blood, 1990, vol. 75, pp. 638-645.
[cited by applicant]
Vajdos et al., “Comprehensive Functional Maps of the Antigen-binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis,” Journal of Molecular Biology, 2002, vol. 320, Iss. 2, pp. 415-428.
[cited by applicant]
Van Der Meeren et al., “Administration of recombinant human interleukin-11 after supralethal radiation exposure promotes survival in mice: interactive effect with thrombopoietin,” Radiat. Res., 2002, vol. 157, pp. 642-6…
[cited by applicant]
Waddick et al., “Comparative Analysis of the in vivo Radioprotective Effects of Recombinant Granulocyte Colony-Stimulating Factor (G-CSF), Recombinant Granulocyte-Macrohage CSF, and Their Combination,” Blood, 1991, vol.…
[cited by applicant]
Warzocha et al., “Antisense Strategy: Biological Utility and Prospects in the Treatment of Hematological Malignancies,” Leukemia and Lymphoma, 2009, vol. 24. Iss. 3-4, pp. 267-281.
[cited by applicant]
Waselenko et al., “Medical Management of the Acute Radiation Syndrome: Recommendations of the Strategic National Stockpile Radiation Working Group”, Annals of Internal Medicine, 2004, vol. 140, Iss. 12, pp. 1037-1051.
[cited by applicant]
Wells, “Additivity of mutational effects in proteins,” Biochemistry, 1990, vol. 29, Iss. 37, pp. 8509-8517.
[cited by applicant]
Wen et al., “Erythropoietin Structure-Function Relationships,” J Biol. Chem., 1994, vol. 269, pp. 22839-22846.
[cited by applicant]
Werle et al. “Strategies to improve plasma half life time of peptide and protein drugs,” Amino Acids, 2006, vol. 30 pp. 351-367.
[cited by applicant]
Whisstock et al. “Prediction of protein function from protein sequence and structure,” Quarterly Reviews of Biophysics, 2003, vol. 36, No. 3, pp. 307-340.
[cited by applicant]
Yang, “Interleukin-11 (IL-11) and its receptor: Biology and potential clinical applications in thrombocytopenia states,” Chapter 13 of Cytokines: Interleukins and Their Receptors, Kurzrock et al., eds., Academic Publish…
[cited by applicant]
Zhang et al., “Effects of human growth hormone on hematopoietic recovery of rats receiving chemotherapy,” Chemotherapy, 2008, vol. 54, pp. 447-455.
[cited by applicant]
Official Action for U.S. Appl. No. 15/269,746 mailed Jun. 15, 2018, 6 pages.
[cited by applicant]
Official Action for U.S. Appl. No. 15/269,746 mailed Dec. 11, 2018, 23 pages.
[cited by applicant]
Official Action for U.S. Appl. No. 15/269,746 mailed Jul. 29, 2019, 22 pages.
[cited by applicant]
Official Action for U.S. Appl. No. 15/269,746, dated Jun. 26, 2020 36 pages.
[cited by applicant]
Official Action for U.S. Appl. No. 15/269,746, dated Mar. 3, 2021 43 pages.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 15/269,746, dated Sep. 17, 2021 14 pages.
[cited by applicant]